Brachytherapy
Volume 6, Issue 4 , Pages 267-271 , October 2007

Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume

  • Joshua H. Petit

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Tel.: +1-617-667-2345; fax: +1-617-667-4990.
    • ,
  • Clifford Gluck

      Affiliations

    • Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • W.S. Kiger III

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • D. Laury Henry

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Carol Karasiewicz

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • James A. Talcott

      Affiliations

    • Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Solomon Berg

      Affiliations

    • Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Edward J. Holupka

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Irving D. Kaplan

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Received 3 April 2007 ,Revised 12 July 2007 ,Accepted 23 August 2007.

References 

  1. Prestidge BR. Radioisotopic implantation for carcinoma of the prostate: Does it work better than it used to?. Semin Radiat Oncol. 1998;8:124–132
  2. Crook J, McLean M, Catton C, et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:453–460
  3. Elshaikh MA, Angermeier K, Ulchaker JC, et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology. 2003;61:152–155
  4. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  5. Hinerman-Mulroy A, Merrick GS, Butler WM, et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59:1367–1382
  6. Lee N, Wu CS, Brody R, et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:1457–1460
  7. Martens C, Pond G, Webster D, et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy. 2006;5:9–13
  8. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:136–143
  9. Schwartz DJ, Schild SE, Wong WW, et al. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:60–63
  10. Terk M, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379–1382
  11. Wang H, Wallner K, Sutlief S, et al. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer. 2000;90:199–205
  12. Merrick GS, Butler WM, Wallner KE, et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;58:81–88
  13. Clark JA, Rieker P, Propert KJ, et al. Changes in quality of life following treatment for early stage prostate cancer. Urology. 1999;53:161–168
  14. Clark JA, Talcott J. Symptom indexes to assess outcomes of treatment for early stage prostate cancer. Med Care. 2001;39:1118–1130

 These data were presented as an oral abstract at the 2005 Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO).

PII: S1538-4721(07)00246-2

doi: 10.1016/j.brachy.2007.08.007

Brachytherapy
Volume 6, Issue 4 , Pages 267-271 , October 2007

Article Tools